IFNA1 and COVID-19: Roughly 10% of COVID-19 patients with severe pneumonia in a cohort of 987 patients had neutralizing autoantibodies against IFNα, IFNω, or both, where patients with no or mild symptoms had no detectable autoantibodies (95).